Hjem › Lymfom › North Carolina
Kliniske studier for Lymfom i North Carolina
22 studier for Lymfom søker deltakere på steder i North Carolina.
Byer i North Carolina
Offisiell studietekst (engelsk)
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Levine Children's Hospital- Pediatric Neuro-Oncology, Charlotte
RekruttererFase 1/2
Opp til 25 år · Alle kjønn · Oppdatert 25. sep. 2026 · NCT04094610CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
- Wake Forest Baptist Medical Center, Winston-Salem
RekruttererFase 2
Alder 18 til 99 · Alle kjønn · Oppdatert 24. sep. 2026 · NCT04083495A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Duke University, Durham
- Novant Health Cancer Institute, Winston-Salem
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07221500CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Duke University Medical Center, Durham
RekruttererFase 1/2
12 Months – 21 Years · Alle kjønn · Oppdatert 11. sep. 2026 · NCT04870944Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- UNC School of Medicine, Division of Hematology, Chapel Hill
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT04588922Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Atrium Health Wake Forest Baptist, Winston-Salem
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT05826535DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill
Rekrutterer
Alder 60 og eldre · Alle kjønn · Oppdatert 14. aug. 2026 · NCT06296368Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
RekruttererFase 1/2
Alder 13 til 90 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 4. aug. 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. jul. 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Duke University Medical Center, Durham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. jul. 2026 · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
- North Carolina Basnight Cancer Hospital, Chapel Hill
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 1. jul. 2026 · NCT06860880Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- og 4 flere
RekruttererObservasjonsstudie
Alder 65 og eldre · Alle kjønn · Oppdatert 29. jun. 2026 · NCT01137825Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Mission Hospital, Asheville
- Wake Forest University Health Sciences, Winston-Salem
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 18. mai 2026 · NCT01790152CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Duke University Medical Center, Duke Cancer Center, Durham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 16. apr. 2026 · NCT03328078A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of North Carolina, Chapel Hill
RekruttererFase 2
Alder 18 til 66 · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06859424A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
- Carolina BioOncology, Huntersville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 4. feb. 2026 · NCT05892718Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
- Duke Cancer Institute, Durham
Rekrutterer
Alder 18 til 39 · Alle kjønn · Oppdatert 28. jan. 2026 · NCT06371768Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. jan. 2026 · NCT04223765Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- Novant Health Breast Surgery - Greensboro, Greensboro
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- og 3 flere
RekruttererFase 3Frivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 13. jan. 2026 · NCT05006482Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
RekruttererObservasjonsstudie
Alder 18 til 120 · Alle kjønn · Oppdatert 27. okt. 2025 · NCT01137643A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Durham VA Medical Center, Durham, NC, Durham
RekruttererFase 2
Alder 18 til 80 · Alle kjønn · Oppdatert 14. okt. 2025 · NCT06520098Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.